All In MedTech

Device Trial Radar · NCT04034810

Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment

Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment, an Observational, Prospective, Single Arm, International, Multicenter Study.

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Nov 4, 2019

Primary completion

Mar 1, 2023

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Balt ExtrusionNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms. All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study. The patient's inclusion and follow up in the study will occur as part of their usual standard of care.

Conditions

  • Intracranial Aneurysm
  • Flow Diverter

Interventions

  • Intracranial aneurysm treated with Silk vista and silk vista babyDevice

    Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.Time frame: At 12-months (-3 / + 6 months) post procedure
  2. Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.Time frame: At 12-months (-3 / + 6 months) post procedure

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Universitätsklinik für Neurologie

    Salzburg, Austria

  • CHC Saint Joseph Liège

    Liège, Belgium

  • University Hospital Centre Zagreb

    Zagreb, Croatia

26 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.